ABC | Volume 111, Nº2, August 2018

Original Article Zhong et al Pioglitazone and VEGFR-2 signaling pathway Arq Bras Cardiol. 2018; 111(2):162-169 1. Dassanayaka S, Jones SP. Recent developments in heart failure. Circ Res. 2015;117(7):e58-63. 2. Braunwald E. Research advances in heart failure: a compendium. Circ Res. 2013;113(6):633-45. 3. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus- mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459-502. 4. EurichDT,McAlisterFA,BlackburnDF,MajumdarSR,TsuyukiRT,Varney J, et al. Benefits andharms of antidiabetic agents inpatientswithdiabetes and heart failure: systematic review. BMJ. 2007;335(7618):497. 5. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129-36. 6. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30(8):2148-53. 7. Varas-LorenzoC,Margulis AV, Pladevall M, Riera-GuardiaN, Calingaert B, Hazell L, et al. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta- analysis of published observational studies. BMC Cardiovasc Disord. 2014 Sep 26;14:129. 8. Biswas A, Rabbani SI, Devi K. Influence of pioglitazone on experimental heart failure and hyperlipidemia in rats. Indian J Pharmacol. 2012;44(3):333-9. 9. Chinnam P, Mohsin M, Shafee LM. Evaluation of acute toxicity of pioglitazone in mice. Toxicol Int. 2012;19(3):250-4. 10. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi- Benedetti M, Moules IK, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89. 11. Wei WY, Ma ZG, Xu SC, Zhang N, Tang QZ. Pioglitazone protected against cardiac hypertrophy via inhibiting AKT/GSK3 β and MAPK signaling pathways. PPAR Res. 2016;2016:9174190. 12. Zhou Y, Bourcy K, Kang YJ. Copper-induced regression of cardiomyocyte hypertrophy is associated with enhanced vascular endothelial growth factor receptor-1 signalling pathway. Cardiovasc Res. 2009;84(1):54-63. 13. Zhao T, Zhao W, Meng W, Liu C, Chen Y, Gerling IC, et al. VEGF-C/ VEGFR-3 pathway promotes myocyte hypertrophy and survival in the infarcted myocardium. Am J Transl Res. 2015;7(4):697-709. 14. Birukova AA, Lee S, Starosta V, Wu T, Ho T, Kim J, et al. A role for VEGFR2 activation in endothelial responses caused by barrier disruptive OxPAPC concentrations. PLoS One. 2012;7(1):e30957. 15. Schwabl P, Payer BA, Grahovac J, Klein S, Horvatits T, Mitterhauser M, et al. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. J Hepatol. 2014;60(6):1135-42. 16. Wang WJ, Huang Q, Zou J, Li LL, Yang SY. TS-Chemscore, a target- specific scoring function, significantly improves the performance of scoring in virtual screening. Chem Biol Drug Des. 2015;86(1):1-8. 17. Fang X, Mei W, Barbazuk WB, Rivkees SA, Wendler CC. Caffeine exposure alters cardiac gene expression in embryonic cardiomyocytes. Am J Physiol Regul Integr Comp Physiol. 2014;307(12):R1471-87. 18. Yu L, She T, Li M, Shi C, Han L, Cheng M. Tetramethylpyrazine inhibits angiotensin II-induced cardiomyocyte hypertrophy and tumor necrosis factor- α secretion through anNF- κ B-dependent mechanism. Int J Mol Med. 2013;32(3):717-22. 19. Feoktistova M, Geserick P, Leverkus M. Crystal violet assay for determining viability of cultured cells. Cold Spring Harb Protoc. 2016;2016(4):pdb.prot087379. 20. Tan A, Cao Y, Xia N, Mo Z, Gao F. The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis. Eur J Intern Med. 2010;21(5):398-403. 21. Suh S, Seo GH, Jung CH, KimMK, Jin SM, Hwang YC, et al. Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the korean health insurance claims database. Diabetes Metab J. 2015;39(3):247-52. 22. Lee HW, Lee HC, Kim BW, Yang MJ, Park JS, Oh JH, et al. Effects of low dose pioglitazone on restenosis and coronary atherosclerosis in diabetic patients undergoing drug eluting stent implantation. Yonsei Med J. 2013;54(6):1313-20. 23. Behringer A, Trappiel M, Berghausen EM, Ten Freyhaus H, Wellnhofer E, Odenthal M, et al. Pioglitazone alleviates cardiac and vascular remodellingand improvessurvival inmonocrotaline inducedpulmonary arterial hypertension. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(4):369-79. 24. SakamotoA,HongoM,FurutaK,SaitoK,NagaiR,IshizakaN.Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension. Int J Cardiol. 2013;167(2):409-15. 25. ChangCS,TsaiPJ,SungJM,ChenJY,HoLC,PandyaK,etal.Diureticsprevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizingeffects inmice.AmJPathol.2014;184(2):442-53. 26. Elshama SS, El-Kenawy Ael-M, Osman HE. Toxicological evaluation of subchronic use of pioglitazone in mice. Iran J Basic Med Sci. 2016;19(7):712-9. 27. Chinnam P, Mohsin M, Shafee LM. Evaluation of acute toxicity of pioglitazone in mice. Toxicol Int. 2012;19(3):250-4. 28. Hoffmann BR, El-Mansy MF, Sem DS, Greene AS. Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity. J Med Chem. 2012;55(19):8260-71. 29. LiZ,BingOH,LongX,RobinsonKG,LakattaEG.Increasedcardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat. Am J Physiol. 1997;272(5 Pt 2):H2313-9. 30. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, et al. Loss of a gp130 cardiacmuscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999;97(2):189-98. 31. Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor- deficient mice. Arterioscler Thromb Vasc Biol. 2007;27(5):1095-100. 32. Bhardwaj S, Roy H, Babu M, Shibuya M, Yla-Herttuala S. Adventitial gene transfer of VEGFR-2 specific VEGF-E chimera induces MCP-1 expression in vascular smooth muscle cells and enhances neointimal formation. Atherosclerosis. 2011;219(1):84-91. 33. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009;21(2):154-65. 34. Sarabipour S, Ballmer-Hofer K, Hristova K. VEGFR-2 conformational switch in response to ligand binding. Elife. 2016 Apr 7;5:e13876. 35. Masuda T, Muto S, Fujisawa G, Iwazu Y, Kimura M, Kobayashi T, et al. Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2012;302(9):H1871-83. 36. ZhengL,HanP,LiuJ,LiR,YinW,WangT,etal.Roleofcopperinregression of cardiac hypertrophy. Pharmacol Ther. 2015 Apr 18;148:66-84. 37. Song HK, Kim J, Lee JS, Nho KJ, Jeong HC, Kim J, et al. Pik3ip1 modulates cardiac hypertrophy by inhibiting PI3K pathway. PLoSOne. 2015;10(3):e0122251. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 168